Ignite Creation Date:
2024-05-06 @ 4:05 PM
Last Modification Date:
2024-10-26 @ 2:03 PM
Study NCT ID:
NCT04863131
Status:
COMPLETED
Last Update Posted:
2023-01-26
First Post:
2021-04-15
Brief Title:
Safety and Immunogenicity of EXG-5003
Sponsor:
Fujita Health University
Organization:
Fujita Health University
Study Overview
Official Title:
Safety and Immunogenicity of Intradermal SARS-CoV-2 Vaccine EXG-5003 in Healthy Adults
Status:
COMPLETED
Status Verified Date:
2023-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a First in Human randomized placebo-controlled Phase III trial to evaluate the safety and immunogenicity of the intradermal COVID-19 vaccine EXG-5003 in healthy adults
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None